Synopsis: Neogen Chemicals posted 34% consolidated revenue growth to Rs 250 crore and 67% profit growth to Rs 17 crore in Q1 FY27, aided by a strong ramp-up at its battery materials subsidiary Neogen Ionics.
India’s specialty chemicals sector is witnessing renewed investor interest in companies positioned around the domestic lithium-ion battery supply chain, as the government pushes localisation through its Production Linked Incentive scheme for Advanced Chemistry Cell manufacturing and battery components.
Shares of Neogen Chemicals surged to Rs 2,202.30, up 6.70% intraday, against a market capitalization of approximately Rs 6,047.79 crore and a 52-week range of Rs 966.70 to Rs 2,374. The stock touched a fresh high earlier this month.
What’s the News?
Neogen Chemicals submitted its earnings presentation titled “Capitalising on Opportunities Rising in Strength” to the BSE and NSE on July 26, 2026, covering unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, in compliance with Regulation 30 of SEBI’s Listing Obligations and Disclosure Requirements Regulations.
Consolidated revenue rose 34% year-on-year to Rs 250 crore from Rs 187 crore, while standalone revenue grew a slightly faster 37% to Rs 252 crore from Rs 185 crore, with the divergence between growth rates at the standalone and consolidated levels reflecting the increasing weight of subsidiary Neogen Ionics in the overall business.
Consolidated EBITDA rose 53% to Rs 48 crore from Rs 32 crore, expanding margins by 260 basis points to 19.3% from 16.9% a year earlier, while consolidated profit after tax climbed 67% to Rs 17 crore from Rs 10 crore, translating into a PAT margin improvement of 130 basis points to 6.8%.
The company separately disclosed that its Board has approved raising up to Rs 600 crore through issue of eligible securities via a Qualified Institutional Placement, in Indian rupees or foreign currency, subject to shareholder and statutory approvals, signalling continued capital requirements to fund its expanding battery materials capacity.
On the Dahej fire incident from March 2025, the company confirmed cumulative recoveries of Rs 164 crore to date, comprising Rs 155 crore in on-account insurance claims, including a fresh Rs 15 crore tranche received in July 2026, and Rs 9 crore from salvage realisation, with a net claim receivable of Rs 186 crore still outstanding on a consolidated basis.
Financial Impact Analysis
The sharpest driver of growth came from Neogen Ionics, the company’s battery chemicals subsidiary, where Q1 FY27 revenue reached Rs 19 crore against just Rs 5 crore in the same quarter last year, an increase management described as exceeding 50% of the unit’s entire prior-year revenue within a single quarter, underscoring the early-stage but rapidly scaling nature of this segment.
Standalone earnings per share rose 32% to Rs 7.15 from Rs 5.40, while consolidated EPS rose a stronger 62% to Rs 6.29 from Rs 3.89, with the wider consolidated gain again reflecting Neogen Ionics moving closer to profitability contribution even as it remains in a heavy capital expenditure phase.
Interest costs rose sharply, up 64% year-on-year on a consolidated basis to Rs 20.8 crore from Rs 12.7 crore, driven by higher debt drawdown to fund ongoing capital expenditure, increased working capital intensity linked to geopolitical supply chain inflation, and delayed insurance receipts, a combination that moderated what would otherwise have been an even stronger profit outcome.
The reconstruction of the Dahej plant is now complete with trial runs underway ahead of commercial production, meaning the temporary drag from toll manufacturing arrangements and expansion overheads that weighed on this quarter’s cost base should ease as the replacement facility ramps toward normal utilisation through the rest of FY27.
Total estimated project cost for the Neogen Ionics Dahej Phase 1 and Pakhajan Phase 2 battery materials projects stands at Rs 1,795 crore, with Rs 218 crore incurred in the June quarter and Rs 1,298 crore cumulatively to date, indicating the bulk of this capital-intensive build-out still lies ahead, reinforcing the rationale behind the proposed Rs 600 crore QIP.
Financial Performance
Standalone EBITDA margin expanded by a modest 30 basis points to 19.1% from 18.8%, a smaller improvement than the consolidated figure, suggesting margin gains were concentrated more at the group level through Neogen Ionics and other subsidiaries rather than in the core standalone bromine and organolithium business.
Standalone profit before tax rose 37% to Rs 26.1 crore from Rs 19.1 crore, with other income more than doubling to Rs 7.9 crore from Rs 3.3 crore, partly cushioning the impact of a 65% jump in standalone interest expense to Rs 23.1 crore from Rs 14 crore.
On a historical basis, consolidated revenue has grown at a 21% five-year compounded annual rate to Rs 862 crore in FY26 from Rs 336 crore in FY21, though consolidated PAT margin has steadily compressed over the same period, falling from 9.3% in FY21 to 3.3% in FY26, reflecting the dilutive effect of heavy investment phases in newer growth segments.
Consolidated net debt has risen sharply to Rs 1,295 crore in FY26 from Rs 530 crore in FY25 and Rs 378 crore in FY24, a trajectory that will need to be watched closely alongside the proposed equity raise, since continued reliance on debt funding for the battery materials build-out would keep interest costs elevated relative to current earnings.
Export sales contributed 30% of consolidated revenue in Q1 FY27, with key geographies including the United States, Europe, China, Korea, Japan and the Middle East, giving the company a geographically diversified customer base for its bromine and lithium-based specialty chemicals.
Industry & Strategic Analysis
Management highlighted that India’s lithium-ion battery sector is backed by a Rs 18,100 crore government outlay to build 50 gigawatt-hours of Advanced Chemistry Cell manufacturing capacity, alongside a rebidding process inviting global bids for a further 10 gigawatt-hours, both of which directly expand the addressable market for Neogen’s electrolyte and lithium salt capacities.
Global demand estimates cited in the presentation point to non-Chinese electrolyte and lithium salt demand rising substantially by 2030, driven partly by United States Foreign Entity of Concern guidelines that require domestic battery cell producers to transition to non-FEOC suppliers by 2027 to retain eligibility for tax credits, a regulatory tailwind that could favour Indian suppliers such as Neogen Ionics.
The company’s provisional approvals from four major international customers and completed site audits with three US-based electrolyte manufacturers for its lithium electrolyte salts business suggest early commercial traction ahead of the broader capacity ramp-up expected through Dahej Phase 1 by February 2027 and Pakhajan Phase 2 by March 2027.
Management flagged that Neogen’s core base business follows a seasonal pattern, typically delivering stronger performance in the second half of the financial year due to European demand cycles and HVAC-linked lithium chemical usage, meaning investors should compare quarterly performance on a year-on-year rather than sequential basis.
Company Overview
Neogen Chemicals Limited, incorporated in 1989 and listed on the BSE and NSE, is one of India’s leading manufacturers of bromine-based and lithium-based specialty chemicals, serving pharmaceutical, agrochemical, electronic chemicals and battery chemicals end markets. The company operates four manufacturing facilities across Maharashtra, Gujarat and Telangana, and its wholly owned subsidiary Neogen Ionics is building dedicated lithium-ion battery materials capacity at Dahej and Pakhajan in Gujarat.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
